DeutschNewstral
Article
Mmarketwatch.com on 2019-01-07 19:32
Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results
Related news
- MSage Therapeutics stock surges 50% on positive trial results in postpartum depressionmarketwatch.com
- MSage Therapeutics shares surge 45% on positive trail of postpartum depression drugmarketwatch.com
Sage Therapeutics surges on postpartum depression drug studywkrg.com- BSage Stock Rises on Postpartum Depression Drug Data3 min readbarrons.com
Postpartum depressionArkansas Online
Sage Therapeutics to seek approval of postpartum depression drug after trial winbizjournals.com- Pill for postpartum depression by Cambridge's Sage succeeds in late-stage trialbizjournals.com
- MSage jumps 8% on expedited development plan for postpartum depression treatmentmarketwatch.com
A Drug For Postpartum Depression? Sage Passes Early Test With Experimental TreatmentForbes- Sage Therapeutics asks FDA to approve lead drug for postpartum depressionbizjournals.com
- New Drug Eases Postpartum Depression In Victory For Tiny Sage TherapeuticsForbes
- Eyeing FDA approval, Sage lays out strategy for dual postpartum depression drugsbizjournals.com
- MFast-acting treatment for postpartum depression, if approved, could help hundreds of thousands of new mothersmarketwatch.com
- NOpinion - Postpartum depressionneweralive.na
Demystifying Postpartum Depressionafro.com
Postpartum depression awarenessuniverse.byu.edu- T15 Postpartum Depression Causestownelaker.com
Woman braves postpartum depressionthecamarilloacorn.com
Postpartum depression drug OK’dnwaonline.com